Barclays analyst Matt Miksic maintains $Edwards Lifesciences (EW.US)$ with a buy rating, and adjusts the target price from $80 to $85.
According to TipRanks data, the analyst has a success rate of 62.2% and a total average return of 7.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
Edwards Lifesciences reported robust sales and earnings, surpassing expectations. The guidance provided for Q4 and the outlook towards 2025 are anticipated to sustain the stock's upward trajectory.
The firm believes that it will require several more quarters for Edwards Lifesciences to persuade investors that it has identified the lowest point for its TAVR franchise, following the third-quarter report.
Expectations were modest prior to the third-quarter results, and the subsequent reports and commentary for the fourth quarter and full year did not suggest that potential negatives were accounted for. Although the slowing trends in fourth-quarter TAVR are attributed to several one-time factors, it's challenging to refute the possibility that TAVR growth may continue to decelerate into the next fiscal year.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
